Header

Sub Navigation

  Close Menu

COVID-19 Treatment Information

At-Home (OTC) Treatment

Over-the-Counter Medications

Your healthcare provider might recommend over-the-counter medications, like acetaminophen or ibuprofen, to help relieve symptoms during a COVID-19 infection. Drinking water to stay hydrated and getting plenty of rest can support the body’s natural defenses and help the body fight the virus.

At-Home Prescription Treatment

These treatments are in very limited supply, and a prescription does not guarantee the medication will be available.

Paxlovid

The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for Pfizer’s Paxlovid for the treatment of mild-to-moderate COVID-19 in people who are 12 years and older, weigh at least 40 kilograms (kg), have tested positive for SARS-CoV-2, and are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid reduced the risk of hospitalization or death among patients with COVID-19 by 88% compared to placebo.

Paxlovid is an antiviral drug that works by blocking an enzyme necessary for the replication of the virus. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Paxlovid is not recommended for people with certain medical conditions and may interact with other prescribed medications.

Molnupiravir

FDA issued an EUA for Merck’s molnupiravir for the treatment of mild-to-moderate COVID-19 in adults 18 and older who have tested positive for SARS-CoV-2, are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Molnupiravir reduced the risk of hospitalization or death among patients with COVID-19 by 30% compared to placebo.

Molnupiravir is an antiviral drug that works by manipulating the enzyme responsible for viral replication. Molnupiravir tricks these enzymes into entering errors in the virus’s genetic code. These errors build up over time until the virus is no longer capable of surviving.

Molnupiravir is not recommended for use during pregnancy as it may cause fetal harm when administered to pregnant individuals. People of childbearing potential are advised to use a reliable method of birth control correctly and consistently during treatment with molnupiravir and for four days after the final dose. People of reproductive potential who are sexually active with people of childbearing potential are advised to use a reliable method of birth control correctly and consistently during treatment with molnupiravir and for at least three months after the final dose.

Molnupiravir is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules. Molnupiravir is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Treatment in a Medical Setting

Remdesivir

FDA has approved remdesivir (Veklury) for the treatment of COVID-19 in hospitalized patients aged 12 years and older who weigh at least 40 kg. It is also available through an FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalized pediatric patients weighing 3.5 kg to fewer than 40 kg or hospitalized pediatric patients younger than 12 years of age weighing at least 3.5 kg.

Remdesivir is an antiviral medication that is given by injection into a vein. The medication works by binding to the enzymes that are necessary for viral replication and preventing them from doing their job. Remdesivir is available by prescription only.

FDA issued an EUA for baricitinib (Olumiant), an immune modulator, in combination with remdesivir (Veklury) for treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients 2 years of age or older and requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygen (ECMO).

Baricitinib tablets are given orally and may help improve health outcomes of COVID-19 by reducing hyperinflammation.

Click for Outpatient Remdesivir Treatment Criteria for Nonhospitalized COVID-19 Patients at Risk for Progression to Severe Disease.


Click an icon on the map below for specific treatment site information.

Monoclonal Antibody Treatment Sites
Merck Antiviral Treatment Sites


Monoclonal Antibody (mAb) Therapies

All mAb therapies are in limited supply and not everyone will be eligible for treatment. A prescription from a healthcare provider is required to receive any mAb therapy. Variants, like Omicron, may have an impact on the effectiveness of mAb treatments. Pending further data, the availability of certain mAb treatments may change based on their effectiveness or ineffectiveness against different variants.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens, like the virus that causes COVID-19. These mAbs block entry into human cells, thus neutralizing the virus. There are four monoclonal antibody therapies that are authorized for use through an EUA. Of these therapies, three may be used during a COVID-19 infection, two may be used after exposure to someone with COVID-19, and one may be used before exposure.

  • REGEN-COV (casirivimab and imdevimab)
    FDA issued EUA for Regeneron’s REGEN-COV for the treatment and post-exposure prevention of COVID-19 in certain individuals. REGEN-COV may treat mild to moderate COVID-19 in those 12 and older who weigh at least 40kg, have a positive COVID-19 test result, and are at high risk for severe illness or hospitalization. REGEN-COV may also be used after exposure (or high risk of exposure) to someone with COVID-19. In this case, REGEN-COV may be effective as post-exposure prevention for people 12 and older who weigh at least 40kg and who have recently been exposed (or have high risk of exposure) and are either immunosuppressed or not fully vaccinated. REGEN-COV can be administered through intravenous (IV) infusion or subcutaneous injection, and it must be given in a healthcare facility.
  • Sotrovimab
    FDA issued EUA for GlaxoSmithKline’s sotrovimab for the treatment for mild to moderate COVID-19 in those 12 and older who weigh at least 40kg, have a positive COVID-19 test result, and are at high risk for severe illness or hospitalization. Sotrovimab can be administered through intravenous (IV) infusion at a healthcare facility. Sotrovimab is the only monoclonal antibody infusion that has been proven effective for people infected with the omicron variant.
  • Bamlanivimab and etesevimab
    FDA issued EUA for Eli Lilly’s bamlanivimab and etesevimab for the treatment and post-exposure prevention of COVID-19 in certain individuals. Bamlanivimab and etesevimab administered together may treat mild to moderate COVID-19 in people of all ages, including newborns, who have a positive COVID-19 test result and are at high risk for severe illness or hospitalization. Bamlanivimab and etesevimab may also be used after exposure (or high risk of exposure) to someone with COVID-19 in certain cases. Bamlanivimab and etesevimab may be effective as post-exposure prevention for people of all ages, including newborns, who have recently been exposed (or have high risk of exposure) and are either immunosuppressed or not fully vaccinated. Bamlanivimab and etesevimab can be administered through intravenous (IV) infusion at a healthcare facility.
  • Evusheld (tixagevimab and cilgavimab)
    FDA issued EUA for AstraZeneca’s Evusheld for the pre-exposure prophylaxis (prevention) of COVID-19 in certain individuals 12 and older who do not currently have COVID-19 and have not recently been exposed to someone with COVID-19. Individuals may be eligible for this pre-exposure prevention treatment if they are moderate to severely immunocompromised and may not mount an adequate immune response to COVID-19 vaccination, or have a history of severe adverse reactions to a COVID-19 vaccine and/or component(s) and are unable to get vaccinated. Evusheld is the only monoclonal antibody therapy that helps prevent COVID-19 infection before exposure to the virus. Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Evusheld can be administered as two separate consecutive intramuscular injections at a healthcare facility.

This medication is in limited supply, so visit this website for updates on availability.

Ask a doctor

Treatments used for COVID-19 should be discussed with a healthcare provider. People have been seriously harmed and even died after taking products not approved for COVID-19, even products approved or prescribed for other uses.

Always check that your information is from a trusted source. If you have questions about any medication, contact the FDA’s Division of Drug Information at 301-796-3400 or druginfo@fda.hhs.gov.


Email Updates
To sign up for updates or to access your subscriber preferences, please enter your contact information below.

This site was last updated Jan 13, 2022 8:49 AM